For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Histologically or cytologically documented extensive-stage small cell lung cancer
             (ES-SCLC) and extensive-stage disease (American Joint Committee on Cancer, 7th
             edition, Stage IV [T any, N any, M1a, or M1b], or T3-4 due to multiple lung nodules
             that are too extensive or tumor or nodal volume that is too large to be encompassed in
             a tolerable radiation plan)

          -  Must provide a fresh tumor biopsy from the primary disease site (when possible) or
             from any metastatic site when the primary site is not available

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1

          -  At least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging
             (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (Response
             Evaluation Criteria in Solid Tumors (RECIST) v1.1) criteria

          -  Adequate hematologic and end organ function

          -  Must agree to follow specific methods of contraception, if applicable

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Prior chemotherapy, radiation therapy, or biologic therapy for small cell lung cancer
             (SCLC) for first-line treatment

          -  Symptomatic brain or other central nervous system (CNS) metastases

          -  Paraneoplastic autoimmune syndrome requiring systemic treatment

          -  History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic
             pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening
             chest CT scan

          -  Grade ≥ 2 peripheral sensory neuropathy at study entry

          -  Significant uncontrolled cardiovascular disease

          -  Active, known or suspected autoimmune disease or inflammatory disorder

        Other protocol-defined inclusion/exclusion criteria apply